Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.

This study found that despite androgen excess and genitourinary masculinization, adult women with congenital adrenal hyperplasia did not exhibit notable prostatic growth.

In this study, docetaxel combined with prednisone significantly extended survival by about 2.5 months in men with hormone-resistant metastatic prostate cancer compared to mitoxantrone plus prednisone, despite the potential for severe adverse effects.

Finasteride may reduce prostate cancer risk.

This study found that higher baseline expression of SRD5A2 in prostate tissue was associated with a better response to finasteride in men with benign prostatic hyperplasia.

This study suggests that extracellular vesicles from prostate cancer cells could aid in identifying tumor heterogeneity and serve as biomarkers, while also playing a role in SARS-CoV-2 infection in nasopharyngeal mucus.

Methylated gene parts may cause finasteride-resistance in some enlarged prostate patients.

This review discusses the role of norepinephrine release and protein kinase C activation in the development of benign prostatic hypertrophy, suggesting potential targets for new therapies, but it reports no new clinical results.

This study reports two cases where localized prostate cancer with low PSA levels was incidentally detected through CT scans performed for other medical reasons.

This editorial comments on long-term treatment options for benign prostatic hyperplasia but reports no new research findings.

A bladder rupture from prostate treatment was healed with catheterization and antibiotics.

This study found that Finasteride treatment significantly reduced dihydrotestosterone and epidermal growth factor levels in benign prostatic hyperplasia tissue, particularly in the periurethral zone, while Flutamide decreased epidermal growth factor but not dihydrotestosterone.

This study concluded that pretreatment with finasteride or bicalutamide did not significantly affect the heat sensitivity of prostate cancer cells, although some cell lines showed increased viability at higher temperatures.

This editorial comment reports no new clinical findings, instead discussing a study on the effectiveness of combination therapy with doxazosin and finasteride in patients with benign prostatic hyperplasia.

This study introduces genital sex differentiation parameters (GSDP) to analyze sexual differences in external genitalia and perineum development in mice, revealing varied sensitivity to androgen inhibition in genital structures.

Using finasteride with TIP extends time off period for prostate cancer patients.

This study reported that treatment with tamsulosin and finasteride significantly improved symptoms and reduced the risk of clinical progression in patients with benign prostatic hyperplasia.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

This case report suggests that spironolactone may induce prostate cancer proliferation in patients on abiraterone acetate, advising against its use for managing treatment-associated side effects in these individuals.

This study found that finasteride-induced DHT deficiency altered estrogen receptor expression in the epididymis, potentially destabilizing its function.

This research suggests that the enzyme Phospholipase D from E. coli is a strong candidate as the underlying cause of benign prostatic hyperplasia, potentially mediated by its conversion to lysophosphatidic acid in the prostate.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

In this study, treatment with finasteride altered the expression patterns of antioxidant enzymes in the epididymis of rats, potentially affecting its protective function for spermatozoa.

This review concludes that preoperative hormonal stimulation with testosterone or DHT may help increase penile length and glans circumference, easing hypospadias surgery and potentially reducing postoperative complications.

This study observed that finasteride therapy reduced PSA levels by about 40% over a year in Chinese patients with benign prostatic hyperplasia, with varying effects based on baseline PSA levels.

Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.

This study reports that prostate volume, operation time, resected tissue weight, and smoking increase risks of blood loss and fluid absorption during PK-TURP, while finasteride treatment and surgeon experience may reduce these risks.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.